Who owns Zentalis Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ZNTL from SEC Form 13F filings across 114 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 114 institutions disclosed 47.4M shares of Zentalis Pharmaceuticals, Inc. worth $228.9M — about 66.4% of shares outstanding; the largest disclosed holder is 5AM Venture Management, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
114
13F holders
$228.9M
value, 2026 filers
66.4%
of shares outstanding (47.4M sh)
33
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ZNTL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 3.9M | $19.1M | 6.7% | 5.5% | 0.0% |
| 2 | BlackRock, Inc. | 3.8M | $18.2M | 0.0% | 5.3% | +195.6% |
| 3 | Squadron Capital Management LLC | 3.7M | $17.9M | 5.6% | 5.2% | +1.9% |
| 4 | TWO SIGMA INVESTMENTS, LP | 3.0M | $14.7M | 0.0% | 4.2% | +2.3% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.8M | $13.8M | 0.0% | 4% | +22.7% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 2.7M | $13.0M | 0.0% | 3.8% | -5.8% |
| 7 | CITADEL ADVISORS LLC | 2.3M | $11.1M | 0.0% | 3.2% | +32.7% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1.6M | $7.8M | 0.0% | 2.3% | -17.0% |
| 9 | Opaleye Management Inc. | 1.4M | $6.9M | 0.6% | 2% | 0.0% |
| 10 | ORBIMED ADVISORS LLCNEW | 1.4M | $6.7M | 0.1% | 1.9% | new |
| 11 | Decheng Capital LLC | 1.3M | $6.4M | 0.9% | 1.9% | 0.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $6.2M | 0.0% | 1.8% | +106.8% |
| 13 | BANK OF AMERICA CORP /DE/ | 1.1M | $5.4M | 0.0% | 1.6% | -1.6% |
| 14 | Ishara Investments LP | 1.0M | $5.0M | 3.7% | 1.4% | -16.7% |
| 15 | PRIMECAP MANAGEMENT CO/CA/ | 957,420 | $4.6M | 0.0% | 1.3% | 0.0% |
| 16 | Pfizer Inc | 953,834 | $3.9M | 2.3% | 1.3% | 0.0% |
| 17 | Soleus Capital Management, L.P.NEW | 950,000 | $4.6M | 0.2% | 1.3% | new |
| 18 | STATE STREET CORP | 887,416 | $4.3M | 0.0% | 1.2% | +255.4% |
| 19 | VANGUARD PORTFOLIO MANAGEMENT LLC | 808,548 | $3.9M | 0.0% | 1.1% | +124.2% |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 758,033 | $3.7M | 0.0% | 1.1% | -4.3% |
| 21 | MILLENNIUM MANAGEMENT LLC | 664,281 | $3.2M | 0.0% | 0.9% | -48.5% |
| 22 | ADAR1 Capital Management, LLC | 652,750 | $3.2M | 0.1% | 0.9% | +351.3% |
| 23 | MARSHALL WACE, LLP | 591,473 | $2.9M | 0.0% | 0.8% | +50.6% |
| 24 | Qube Research & Technologies Ltd | 574,806 | $2.8M | 0.0% | 0.8% | -9.8% |
| 25 | D. E. Shaw & Co., Inc. | 546,566 | $2.7M | 0.0% | 0.8% | -63.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.